RBC Capital Sees Eli Lilly’s (LLY) Retatrutide as Key Growth Driver despite Mixed Trial Results.
Share this article
Corporate
Score 72
Bullish
RBC Capital Sees Eli Lilly’s (LLY) Retatrutide as Key Growth Driver despite Mixed Trial Results
Mar 20, 2026 04:03 UTC
LLY, XLV, IBB
Medium term
Related Articles
Score 85
Bearish
Elon Musk misled Twitter investors ahead of $44 billion acquisition, jury says
Mar 20, 23:29
Score 65
Netflix Expands Live Event Strategy with BTS Comeback Spectacular
Mar 20, 23:00
Score 72
Bullish
Nuclear Energy Firm X-Energy Files for US IPO Despite War
Mar 20, 22:53
Score 35
Activist Investor Jonathan Litt Withdraws Board Bid for First Industrial REIT
Mar 20, 21:48
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.